Transverse myelitis is an acquired inflammatory disorder of the spinal cord that can cause rapid onset motor, sensory, and autonomic neurologic deficits. It is a syndrome rather than a single etiology: acute transverse myelitis may be idiopathic or secondary to systemic autoimmune disease, infection, NMOSD, MOGAD, multiple sclerosis, or other neuroinflammatory disorders.
Ask a research question about Transverse Myelitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Transverse Myelitis
creation_date: '2026-02-01T23:53:45Z'
updated_date: "2026-05-17T06:27:35Z"
category: Neurological Disorder
parents:
- Autoimmune Disorder
- Demyelinating Disease
disease_term:
preferred_term: transverse myelitis
term:
id: MONDO:0021553
label: transverse myelitis
mappings:
icd10cm_mappings:
- term:
id: ICD10CM:G37.3
label: Acute transverse myelitis in demyelinating disease of central nervous system
mapping_predicate: skos:closeMatch
mapping_source: ICD-10-CM
mapping_justification: ICD-10-CM code is for acute transverse myelitis within demyelinating CNS disease.
consistency:
- reference: MONDO
consistent: MISSING
icd11f_mappings:
- term:
id: icd11f:1328350091
label: Transverse myelitis
mapping_predicate: skos:exactMatch
mapping_source: ICD-11 Foundation
mapping_justification: ICD-11 Foundation term matches transverse myelitis.
consistency:
- reference: MONDO
consistent: CONSISTENT
mondo_mappings:
- term:
id: MONDO:0021553
label: transverse myelitis
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: Primary MONDO disease term for this entry.
description: >-
Transverse myelitis is an acquired inflammatory disorder of the spinal cord
that can cause rapid onset motor, sensory, and autonomic neurologic deficits.
It is a syndrome rather than a single etiology: acute transverse myelitis may
be idiopathic or secondary to systemic autoimmune disease, infection, NMOSD,
MOGAD, multiple sclerosis, or other neuroinflammatory disorders.
has_subtypes:
- name: Acute TM
display_name: Acute transverse myelitis
subtype_term:
preferred_term: acute transverse myelitis
term:
id: MONDO:0015342
label: acute transverse myelitis
description: >-
Acute inflammatory demyelinating myelitis of the spinal cord; MONDO and
Orphanet distinguish this acute syndrome from the broader transverse
myelitis concept.
evidence:
- reference: PMID:12045735
reference_title: "Immunopathogenesis of acute transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Acute transverse myelitis is a group of disorders characterized by focal inflammation of the spinal cord and resultant neural injury."
explanation: >
This review supports acute transverse myelitis as an inflammatory spinal
cord syndrome and justifies the acute subtype grounding.
- name: Idiopathic ATM
display_name: Idiopathic acute transverse myelitis
subtype_term:
preferred_term: idiopathic acute transverse myelitis
term:
id: MONDO:0015344
label: idiopathic acute transverse myelitis
description: >-
Acute transverse myelitis for which initial evaluation does not identify a
more specific relapsing, systemic autoimmune, infectious, or demyelinating
disease; long follow-up is needed because some apparently idiopathic first
episodes later recur.
evidence:
- reference: PMID:25340060
reference_title: "Predictors of recurrence following an initial episode of transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In many circumstances, however, the evaluation of an initial TM event does not yield sufficient historical, clinical, radiologic, or laboratory data to meet diagnostic criteria for an underlying condition."
explanation: >
This cohort paper describes the common clinical situation in which a first
TM episode is initially classified as idiopathic because no underlying
disorder is confirmed.
- name: MOG-IgG ATM
display_name: Acute transverse myelitis with anti-MOG antibodies
subtype_term:
preferred_term: acute transverse myelitis with anti-MOG antibodies
term:
id: MONDO:0035666
label: acute transverse myelitis with anti-MOG antibodies
description: >-
Acute transverse myelitis occurring in the setting of MOG-IgG-associated
disease, clinically important because MOGAD is a distinct diagnostic and
prognostic category rather than seronegative NMOSD.
evidence:
- reference: PMID:23999580
reference_title: "Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Thus, we suggest that diagnoses such as myelin-oligodendrocyte glycoprotein antibody disease, multiple sclerosis, acute disseminated encephalomyelitis, and postinfectious disorders should be exclusions in the NMO diagnostic criteria and AQP4-Ab-positive and antibody-negative NMO/NMO spectrum disorder cohorts should be analyzed separately."
explanation: >
The LETM cohort explicitly identifies MOG antibody disease as a separate
diagnostic category to consider in myelitis differential diagnosis.
definitions:
- name: Clinical presentation summary (StatPearls)
definition_type: CASE_DEFINITION
description: >-
Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often
presenting with rapid onset weakness, sensory deficits, and bowel/bladder
dysfunction.
criteria_sets:
- name: Common presenting features
core_clinical_characteristics:
- preferred_term: Rapid onset weakness
term:
id: HP:0001324
label: Muscle weakness
description: Rapid onset muscle weakness.
- preferred_term: Sensory deficits
term:
id: HP:0003474
label: Somatic sensory dysfunction
- preferred_term: Neurogenic bladder
term:
id: HP:0000011
label: Neurogenic bladder
- preferred_term: Bowel incontinence
term:
id: HP:0002607
label: Bowel incontinence
evidence:
- reference: PMID:32644728
reference_title: "Transverse Myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction."
explanation: >
The StatPearls abstract directly lists the motor, sensory, bladder, and
bowel features used as the criteria-set core characteristics.
evidence:
- reference: PMID:32644728
reference_title: "Transverse Myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction."
explanation: The abstract summarizes common presenting features used here as a minimal case definition.
pathophysiology:
- name: Spinal Cord Inflammation
description: >-
Focal inflammatory injury within the spinal cord disrupts motor and sensory
pathways, leading to neurologic deficits.
locations:
- preferred_term: spinal cord
term:
id: UBERON:0002240
label: spinal cord
biological_processes:
- preferred_term: inflammatory response
modifier: INCREASED
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:32644728
reference_title: "Transverse Myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction."
explanation: The abstract defines transverse myelitis as a focal inflammatory disorder of the spinal cord.
- reference: PMID:12045735
reference_title: "Immunopathogenesis of acute transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Acute transverse myelitis is a group of disorders characterized by focal inflammation of the spinal cord and resultant neural injury."
explanation: The review describes focal spinal cord inflammation with neural injury as a defining feature.
- name: Perivascular Immune Cell Infiltration
description: >-
In idiopathic acute transverse myelitis, immune cells enter intraparenchymal
or perivascular spinal cord compartments.
locations:
- preferred_term: spinal cord
term:
id: UBERON:0002240
label: spinal cord
cell_types:
- preferred_term: monocyte
term:
id: CL:0000576
label: monocyte
downstream:
- target: Blood-Brain Barrier Breakdown
description: >
Perivascular and intraparenchymal inflammatory infiltrates precede
disruption of the blood-brain barrier.
evidence:
- reference: PMID:12045735
reference_title: "Immunopathogenesis of acute transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In idiopathic acute transverse myelitis, there is an intraparenchymal or perivascular cellular influx into the spinal cord, resulting in the breakdown of the blood-brain barrier and variable demyelination and neuronal injury."
explanation: >
This statement explicitly links cellular influx with breakdown of the
blood-brain barrier.
evidence:
- reference: PMID:12045735
reference_title: "Immunopathogenesis of acute transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In idiopathic acute transverse myelitis, there is an intraparenchymal or perivascular cellular influx into the spinal cord, resulting in the breakdown of the blood-brain barrier and variable demyelination and neuronal injury."
explanation: >
The abstract directly describes intraparenchymal or perivascular cellular
influx into the spinal cord in idiopathic acute TM.
- name: Blood-Brain Barrier Breakdown
description: >-
Inflammatory cellular influx in acute transverse myelitis is associated with
breakdown of the blood-brain barrier.
locations:
- preferred_term: blood brain barrier
modifier: ABNORMAL
term:
id: UBERON:0000120
label: blood brain barrier
downstream:
- target: Demyelination and Neuronal Injury
description: >
Barrier breakdown permits inflammatory injury that converges on myelin and
neuronal damage in the spinal cord.
evidence:
- reference: PMID:12045735
reference_title: "Immunopathogenesis of acute transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In idiopathic acute transverse myelitis, there is an intraparenchymal or perivascular cellular influx into the spinal cord, resulting in the breakdown of the blood-brain barrier and variable demyelination and neuronal injury."
explanation: >
This statement links barrier breakdown to downstream demyelination and
neuronal injury in idiopathic acute TM.
evidence:
- reference: PMID:12045735
reference_title: "Immunopathogenesis of acute transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In idiopathic acute transverse myelitis, there is an intraparenchymal or perivascular cellular influx into the spinal cord, resulting in the breakdown of the blood-brain barrier and variable demyelination and neuronal injury."
explanation: >
The same immunopathogenesis abstract identifies blood-brain barrier
breakdown as the downstream consequence of cellular influx.
- name: Demyelination and Neuronal Injury
description: >-
Acute inflammatory spinal cord injury in transverse myelitis causes variable
demyelination and neuronal injury.
locations:
- preferred_term: spinal cord
term:
id: UBERON:0002240
label: spinal cord
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
cellular_components:
- preferred_term: myelin sheath
modifier: DECREASED
term:
id: GO:0043209
label: myelin sheath
evidence:
- reference: PMID:12045735
reference_title: "Immunopathogenesis of acute transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In idiopathic acute transverse myelitis, there is an intraparenchymal or perivascular cellular influx into the spinal cord, resulting in the breakdown of the blood-brain barrier and variable demyelination and neuronal injury."
explanation: >
The abstract supports demyelination and neuronal injury as distinct tissue
consequences of acute idiopathic TM inflammation.
- name: Immune-Mediated Spinal Cord Disorder
description: >-
Transverse myelitis is an immune-mediated disorder of the spinal cord that
causes motor and sensory disturbance, with limited recovery in a subset of
patients.
evidence:
- reference: PMID:26009577
reference_title: "Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transverse myelitis (TM) is an immune-mediated disorder of the spinal cord which causes motor and sensory disturbance and limited recovery in 50% of patients."
explanation: The abstract defines TM as immune-mediated and notes motor/sensory disturbance with limited recovery.
- name: Recurrent Neuroinflammatory Disease Risk
description: >-
A first transverse myelitis episode can later declare itself as recurrent
myelitis, NMOSD, or a systemic autoimmune disorder; LETM, CSF inflammatory
markers, AQP4-IgG and related serologies are therefore mechanistically and
prognostically important.
locations:
- preferred_term: spinal cord
term:
id: UBERON:0002240
label: spinal cord
biological_processes:
- preferred_term: humoral immune response
modifier: INCREASED
term:
id: GO:0006959
label: humoral immune response
evidence:
- reference: PMID:25340060
reference_title: "Predictors of recurrence following an initial episode of transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "One hundred ten of 192 patients (57%) eventually developed recurrent symptoms: 69 (63%) neuromyelitis optica (NMO) or NMO spectrum disorder, 34 (31%) non-NMO recurrent TM, and 7 (6%) systemic autoimmune disease."
explanation: >
This cohort supports recurrence and later diagnostic reclassification as
key features to model for initially unexplained transverse myelitis.
phenotypes:
- name: Muscle Weakness
category: Neurologic
frequency: COMMON
phenotype_term:
preferred_term: Muscle weakness
term:
id: HP:0001324
label: Muscle weakness
evidence:
- reference: PMID:32644728
reference_title: "Transverse Myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction."
explanation: Rapid onset weakness is a key presenting feature of transverse myelitis.
- name: Sensory Disturbance
category: Neurologic
frequency: COMMON
phenotype_term:
preferred_term: Sensory disturbance
term:
id: HP:0003474
label: Somatic sensory dysfunction
evidence:
- reference: PMID:32644728
reference_title: "Transverse Myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction."
explanation: Sensory deficits are listed among common presenting features of transverse myelitis.
- name: Back Pain
category: Neurologic
frequency: OCCASIONAL
phenotype_term:
preferred_term: back pain
term:
id: HP:0003418
label: Back pain
evidence:
- reference: PMID:34171586
reference_title: "Longitudinally extensive transverse myelitis in childhood: Clinical features, treatment approaches, and long-term neurological outcomes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Presenting symptoms included inability to walk in 12 patients, incontinence in 9 patients, low back pain in 4 patients, abdominal pain in 2 patients, and inability to use the arms in 2 patients."
explanation: >
This pediatric LETM cohort directly reports low back pain in 4/15
patients, which is 27% and falls in the OCCASIONAL band.
- reference: PMID:26351447
reference_title: "Pediatric Acute Longitudinal Extensive Transverse Myelitis Secondary to Neuroborreliosis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Remarkably, the patient reported only mild symptoms with severe back pain in the absence of profound signs of myelopathy."
explanation: >
The neuroborreliosis-associated LETM case review provides an additional
direct example of severe back pain in transverse myelitis.
- name: Neurogenic Bladder
category: Genitourinary
frequency: COMMON
phenotype_term:
preferred_term: Neurogenic bladder
term:
id: HP:0000011
label: Neurogenic bladder
evidence:
- reference: PMID:32644728
reference_title: "Transverse Myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction."
explanation: Bladder dysfunction is listed as a presenting feature of transverse myelitis.
- name: Bowel Incontinence
category: Gastrointestinal
frequency: COMMON
phenotype_term:
preferred_term: Bowel incontinence
term:
id: HP:0002607
label: Bowel incontinence
evidence:
- reference: PMID:32644728
reference_title: "Transverse Myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transverse myelitis (TM) is a rare, acquired focal inflammatory disorder often presenting with rapid onset weakness, sensory deficits, and bowel/bladder dysfunction."
explanation: Bowel dysfunction is listed among presenting features of transverse myelitis.
- name: Paraplegia
category: Neurologic
frequency: COMMON
phenotype_term:
preferred_term: Paraplegia
term:
id: HP:0010550
label: Paraplegia
evidence:
- reference: PMID:32644728
reference_title: "Transverse Myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At peak deficit, 50% of patients are completely paraplegic, with virtually all of the patients having a degree of bladder/bowel dysfunction."
explanation: The abstract notes paraplegia in a substantial fraction of patients at peak deficit.
- name: Longitudinally Extensive Transverse Myelitis
category: Neurologic
frequency: FREQUENT
phenotype_term:
preferred_term: longitudinally extensive transverse myelitis
term:
id: HP:0012486
label: Myelitis
spatial_extent: EXTENSIVE
notes: >
HPO lacks a specific LETM term, so HP:0012486 (Myelitis) is used with
spatial_extent=EXTENSIVE to encode involvement of three or more vertebral
segments.
evidence:
- reference: PMID:25340060
reference_title: "Predictors of recurrence following an initial episode of transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Multiple independent risk factors for recurrence were identified: African American race (risk ratio 1.60, p < 0.001, 95% confidence interval 1.26-2.03; similarly noted hereafter), female sex (1.88, p = 0.007, 1.19-2.98), longitudinally extensive myelitis at onset (1.34, p = 0.036, 1.01-1.78), Sjogren syndrome antigen A (1.89, p = 0.003, 1.44-2.48), vitamin D insufficiency (4.00, p < 0.001, 1.60-10.0), antinuclear antibody titer ≥1:160 (1.69, p = 0.006, 1.23-2.32), and the presence of inflammatory markers (e.g., immunoglobulin G index) in the CSF (2.14, p < 0.001, 1.44-3.17)."
explanation: >
The recurrence cohort identifies longitudinally extensive myelitis at
onset as a clinically important TM presentation and prognostic feature.
- reference: PMID:42003147
reference_title: "A Clinical Profile of Transverse Myelitis with Special Reference to Outcomes: A 5-Year Retrospective Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "About 76.7% had longitudinally extensive transverse myelitis (LETM)."
explanation: >
The 2026 retrospective TM cohort reports LETM as a common imaging pattern.
- name: Tonic Spasms
category: Neurologic
frequency: COMMON
phenotype_term:
preferred_term: tonic spasms
term:
id: HP:0011964
label: Intermittent painful muscle spasms
evidence:
- reference: PMID:38977461
reference_title: "Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a prospective observational study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most frequent spinal movement disorders were tonic spasms (57%), focal dystonia (25%), spinal tremor (16%), spontaneous clonus (9.5%), secondary restless limb syndrome (9.5%), and spinal myoclonus (8%)."
explanation: >
This prospective non-MS spinal demyelination study reports tonic spasms
as the most frequent spinal movement disorder, including idiopathic TM
among the compared groups.
- name: Spasticity
category: Neurologic
phenotype_term:
preferred_term: spasticity
term:
id: HP:0001257
label: Spasticity
evidence:
- reference: PMID:29270309
reference_title: "Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Analyses of secondary clinical outcome measures including strength, balance assessments, spasticity, and Expanded Disability Status Scale (EDSS) score showed trends toward improvement with D-ER."
explanation: >
The TM dalfampridine trial includes spasticity as a clinical outcome,
supporting it as a relevant post-acute motor phenotype without providing
cohort frequency data.
- reference: PMID:35246251
reference_title: "Physiotherapy management of acute transverse myelitis in a pediatric patient in a Nigerian hospital: a case report."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The patient presented with severe muscle spasms and frequent jerking movements, shocking sensations, hypertonicity, and spasticity (modified Ashworth scale: 1+ on the right, > 2 on the right), and muscle strength of the lower limbs (Oxford muscle grading: 3/5 on the left, 1/5 on the left) with impaired functional status (Functional Independence Measure: 70/126)."
explanation: >
This acute TM rehabilitation case report directly documents measured
spasticity and hypertonicity as part of the clinical presentation.
- name: Focal Dystonia
category: Neurologic
frequency: OCCASIONAL
phenotype_term:
preferred_term: focal dystonia
term:
id: HP:0004373
label: Focal dystonia
evidence:
- reference: PMID:38977461
reference_title: "Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a prospective observational study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most frequent spinal movement disorders were tonic spasms (57%), focal dystonia (25%), spinal tremor (16%), spontaneous clonus (9.5%), secondary restless limb syndrome (9.5%), and spinal myoclonus (8%)."
explanation: >
The prospective cohort quantifies focal dystonia among spinal movement
disorders seen after inflammatory spinal cord demyelination.
biochemical:
- name: Interleukin-6
presence: Elevated
context: PBMC supernatants
evidence:
- reference: PMID:18417225
reference_title: "Interleukin-17 in transverse myelitis and multiple sclerosis."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "IL-6 was increased in TM relative to MS and HC (HC: 2624 pg/ml+/-641, MS: 6129+/-982, TM: 12,536+/-2657, OND: 6920+/-1801, p<0.002)."
explanation: IL-6 was elevated in stimulated PBMC supernatants from TM patients relative to MS and healthy controls.
- name: Interleukin-17
presence: Elevated
context: PBMC supernatants
evidence:
- reference: PMID:18417225
reference_title: "Interleukin-17 in transverse myelitis and multiple sclerosis."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "IL-17 was increased in TM compared to HC, MS, and OND (mean pg/ml+/-standard error; HC: 36.1+/-11.7, MS: 89.4+/-23.3, TM: 302.6+/-152.5, OND: 41.2+/-13.0, p=0.01)."
explanation: IL-17 is increased in TM relative to control and comparator groups.
- name: AQP4-IgG
presence: Positive in subset
context: Longitudinally extensive transverse myelitis cohort
notes: AQP4-Ab positivity was reported in a LETM cohort.
evidence:
- reference: PMID:23999580
reference_title: "Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Fifty-eight percent of patients were AQP4-Ab positive."
explanation: Reports the proportion of LETM patients with AQP4 antibody positivity.
- name: CSF Inflammatory Markers
presence: Positive
context: Initial transverse myelitis episode
evidence:
- reference: PMID:25340060
reference_title: "Predictors of recurrence following an initial episode of transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Multiple independent risk factors for recurrence were identified: African American race (risk ratio 1.60, p < 0.001, 95% confidence interval 1.26-2.03; similarly noted hereafter), female sex (1.88, p = 0.007, 1.19-2.98), longitudinally extensive myelitis at onset (1.34, p = 0.036, 1.01-1.78), Sjogren syndrome antigen A (1.89, p = 0.003, 1.44-2.48), vitamin D insufficiency (4.00, p < 0.001, 1.60-10.0), antinuclear antibody titer ≥1:160 (1.69, p = 0.006, 1.23-2.32), and the presence of inflammatory markers (e.g., immunoglobulin G index) in the CSF (2.14, p < 0.001, 1.44-3.17)."
explanation: >
CSF inflammatory markers, including IgG index, were associated with
recurrent disease after an initial TM episode.
- name: Serum Neurofilament Light Chain
presence: Elevated during acute attacks
context: Idiopathic transverse myelitis
evidence:
- reference: PMID:36894677
reference_title: "Disease characteristics of idiopathic transverse myelitis with serum neuronal and astroglial damage biomarkers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Compared to HCs, ITM patients showed higher sNfL and sGFAP during acute attacks (sNfL: p < 0.001, sGFAP: p = 0.024), while those in remission (sNfL: p = 0.944, sGFAP: p > 0.999) did not, regardless of lesion extents and presence of multiple attacks."
explanation: >
This prospective biomarker cohort supports serum neurofilament light
chain elevation during acute idiopathic TM attacks, with normalization in
remission.
- name: Serum Glial Fibrillary Acidic Protein
presence: Elevated during acute attacks
context: Idiopathic and seropositive transverse myelitis comparison
notes: >
GFAP elevation during acute idiopathic TM attacks is lower than in
seropositive AQP4/MOG-associated TM, supporting biomarker use in subtype
discrimination.
evidence:
- reference: PMID:36894677
reference_title: "Disease characteristics of idiopathic transverse myelitis with serum neuronal and astroglial damage biomarkers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Compared to HCs, ITM patients showed higher sNfL and sGFAP during acute attacks (sNfL: p < 0.001, sGFAP: p = 0.024), while those in remission (sNfL: p = 0.944, sGFAP: p > 0.999) did not, regardless of lesion extents and presence of multiple attacks."
explanation: >
Serum GFAP is elevated during acute idiopathic TM attacks but not in
remission in this cohort.
- reference: PMID:37688927
reference_title: "Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "GFAP levels could be a promising biomarker to differentiate iTM from sTM."
explanation: >
The multicenter biomarker study supports GFAP as a candidate marker for
distinguishing idiopathic TM from antibody-associated seropositive TM.
progression:
- phase: Acute presentation
notes: >
TM typically begins rapidly with bilateral motor and sensory symptoms, often
with bladder, bowel, or sexual dysfunction.
evidence:
- reference: PMID:42003147
reference_title: "A Clinical Profile of Transverse Myelitis with Special Reference to Outcomes: A 5-Year Retrospective Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transverse myelitis (TM), a rare inflammatory condition affecting the spinal cord, presents with a rapid onset of bilateral motor and sensory symptoms with or without bladder/bowel and sexual dysfunction."
explanation: >
The 2026 retrospective cohort summarizes the typical acute clinical
presentation of transverse myelitis.
- phase: Recovery and residual disability
notes: >
Outcome is variable: some patients recover completely, while others retain
moderate or severe disability after the acute episode.
evidence:
- reference: PMID:32644728
reference_title: "Transverse Myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Approximately 33% of patients recover with little to no lasting deficits, 33% have a moderate degree of permanent disability, and 33% are permanently disabled."
explanation: >
StatPearls gives the commonly cited one-third/one-third/one-third outcome
distribution after TM.
- reference: PMID:42003147
reference_title: "A Clinical Profile of Transverse Myelitis with Special Reference to Outcomes: A 5-Year Retrospective Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At follow-up, nearly 30% of the respondents reported complete recovery, while 8.3% reported worsening."
explanation: >
The 2026 cohort provides more recent long-term outcome data.
- phase: COVID-19-associated transverse myelitis phenotype
notes: >
Post-COVID-19 infection TM may present with more severe deficits, more
extensive spinal cord involvement, poorer six-month outcomes, and more
frequent need for immunotherapy escalation than idiopathic TM.
evidence:
- reference: PMID:41349230
reference_title: "Transverse myelitis following COVID-19 infection or vaccination: Clinical outcomes and imaging characteristics compared with idiopathic cases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "PITM is associated with more severe deficits, extensive spinal cord involvement, and poorer outcomes than PVTM and ITM."
explanation: >
This 2026 retrospective comparison separates post-infection,
post-vaccination, and idiopathic TM phenotypes and reports the most severe
outcomes in post-infection TM.
- phase: Recurrence risk assessment
notes: >
Recurrence risk is highest when the first episode has LETM, CSF inflammatory
markers, high-risk serologies, or later-definable NMOSD/systemic autoimmune
disease.
evidence:
- reference: PMID:25340060
reference_title: "Predictors of recurrence following an initial episode of transverse myelitis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "One hundred ten of 192 patients (57%) eventually developed recurrent symptoms: 69 (63%) neuromyelitis optica (NMO) or NMO spectrum disorder, 34 (31%) non-NMO recurrent TM, and 7 (6%) systemic autoimmune disease."
explanation: >
This cohort shows that more than half of initially unexplained TM patients
referred to a tertiary center ultimately developed recurrent disease.
treatments:
- name: Corticosteroid Therapy
description: High-dose steroids as standard acute therapy.
treatment_term:
preferred_term: corticosteroid agent therapy
term:
id: MAXO:0000640
label: corticosteroid agent therapy
evidence:
- reference: PMID:26009577
reference_title: "Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Standard treatment is steroids, and patients with more severe disease appear to respond to plasma exchange (PLEX)."
explanation: The abstract states steroids are standard treatment for transverse myelitis.
- name: Plasma Exchange
description: Plasma exchange for more severe transverse myelitis.
treatment_term:
preferred_term: plasma exchange
term:
id: NCIT:C15304
label: Plasmapheresis
notes: NCIT provides the specific treatment-action term for plasmapheresis.
evidence:
- reference: PMID:26009577
reference_title: "Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Standard treatment is steroids, and patients with more severe disease appear to respond to plasma exchange (PLEX)."
explanation: The abstract notes plasma exchange responsiveness in severe transverse myelitis.
- name: Intravenous Immunoglobulin Adjunctive Therapy
description: >
IVIG has been studied as an adjunct to intravenous methylprednisolone for
first-episode transverse myelitis, but the STRIVE protocol notes that
evidence was lacking at trial design.
treatment_term:
preferred_term: intravenous immunoglobulin therapy
term:
id: NCIT:C121331
label: Intravenous Immunoglobulin Therapy
evidence:
- reference: PMID:26009577
reference_title: "Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Intravenous immunoglobulin (IVIG) has also been used as an adjunct to steroids, but evidence is lacking."
explanation: >
The STRIVE protocol supports IVIG as a studied adjunctive therapy while
explicitly noting the evidence gap that motivated the trial.
clinical_trials:
- name: NCT02398994
phase: PHASE_III
status: TERMINATED
description: >
STRIVE was a multicenter randomized trial evaluating whether adding IVIG to
corticosteroids improves outcomes in children and adults with first-episode
transverse myelitis or NMO-associated myelitis.
target_phenotypes:
- preferred_term: Myelitis
term:
id: HP:0012486
label: Myelitis
- preferred_term: Muscle weakness
term:
id: HP:0001324
label: Muscle weakness
evidence:
- reference: clinicaltrials:NCT02398994
reference_title: "A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin (IVIg) Versus Standard Therapy for the Treatment of Transverse Myelitis in Adults and Children"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This multi-center randomized controlled trial evaluates if the addition of intravenous immunoglobulin to standard treatment of corticosteroids improves outcome in children and adults with first episode of Transverse Myelitis of Neuro-myelitis optica."
explanation: >
ClinicalTrials.gov identifies NCT02398994 as the phase III STRIVE trial
testing IVIG plus corticosteroids for first-episode TM/NMO-associated
myelitis.
references:
- reference: clinicaltrials:NCT02398994
title: A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin (IVIg) Versus Standard Therapy for the Treatment of Transverse Myelitis in Adults and Children
findings: []
- reference: PMID:25340060
title: Predictors of recurrence following an initial episode of transverse myelitis.
findings: []
- reference: DOI:10.1007/s00415-024-12527-6
title: 'Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a prospective observational study'
findings: []
- reference: PMID:38977461
title: 'Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a prospective observational study.'
findings: []
- reference: PMID:34171586
title: "Longitudinally extensive transverse myelitis in childhood: Clinical features, treatment approaches, and long-term neurological outcomes."
findings: []
- reference: PMID:26351447
title: Pediatric Acute Longitudinal Extensive Transverse Myelitis Secondary to Neuroborreliosis.
findings: []
- reference: PMID:29270309
title: "Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis."
findings: []
- reference: PMID:35246251
title: "Physiotherapy management of acute transverse myelitis in a pediatric patient in a Nigerian hospital: a case report."
findings: []
- reference: DOI:10.1016/j.amsu.2022.103870
title: 'The association between SARS-CoV-2 vaccines and transverse myelitis: A review'
findings: []
- reference: PMID:42003147
title: 'A Clinical Profile of Transverse Myelitis with Special Reference to Outcomes: A 5-Year Retrospective Study.'
findings: []
- reference: PMID:36894677
title: Disease characteristics of idiopathic transverse myelitis with serum neuronal and astroglial damage biomarkers.
findings: []
- reference: PMID:37688927
title: Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis.
findings: []
- reference: PMID:41349230
title: "Transverse myelitis following COVID-19 infection or vaccination: Clinical outcomes and imaging characteristics compared with idiopathic cases."
findings: []
- reference: DOI:10.1055/s-0044-1789342
title: 'Longitudinally-extensive transverse myelitis: impact on functional prognosis and mortality in a 10-year follow-up cohort'
findings: []
- reference: DOI:10.1055/s-0045-1806986
title: Acute transverse myelitis secondary to schistosomiasis
findings: []
- reference: DOI:10.1056/nejmcp1001112
title: Transverse Myelitis
findings: []
- reference: DOI:10.1126/scitranslmed.aai9111
title: Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica
findings: []
- reference: DOI:10.1212/01.con.0000403797.10612.d3
title: Rehabilitation in Transverse Myelitis
findings: []
- reference: DOI:10.1212/01.con.0001097968.42765.7a
title: AUTOIMMUNE TRANSVERSE MYELITIS
findings: []
- reference: DOI:10.1212/nxi.0000000000000004
title: Predictors of recurrence following an initial episode of transverse myelitis
findings: []
- reference: DOI:10.1212/nxi.0000000000200529
title: Astrocyte Biology in CNS Inflammatory Diseases
findings: []
- reference: DOI:10.1590/s1678-9946202466066
title: 'Zika virus infection and acute transverse myelitis: a comprehensive systematic review'
findings: []
- reference: DOI:10.3389/fmed.2025.1506201
title: 'Acute transverse myelitis caused by Paragonimus infection: a case report and review of the literature'
findings: []
- reference: PMID:32979043
title: Genetic factors for susceptibility to and manifestations of neuromyelitis optica.
findings: []
Disease Pathophysiology Research Report
Target Disease - Disease Name: Transverse Myelitis (TM) - Category: Neurological Disorder
Pathophysiology description Transverse myelitis is an acute or subacute immune-mediated inflammatory syndrome of the spinal cord characterized by motor, sensory, and autonomic dysfunction, often following infection or vaccination, with 15–30% of cases remaining idiopathic. Histopathology shows focal perivascular collections of lymphocytes and monocytes, with variable demyelination, axonal injury, and activation of astroglia and microglia. In neuromyelitis optica spectrum disorder (NMOSD), lesions exhibit perivascular immunoglobulin and complement deposition and, in severe cases, necrosis, supporting antibody- and complement-mediated astrocytopathy as a core mechanism. MRI evidence of cord inflammation typically includes gadolinium enhancement of intramedullary lesions; CSF may show pleocytosis and/or elevated IgG index. Symptoms evolve over hours to days and reach nadir within ~4 hours to 21 days; most recovery occurs within 3 months but may continue up to one year (NEJM review; Aug 2010; https://doi.org/10.1056/NEJMcp1001112) (frohman2010transversemyelitis pages 1-2, frohman2010transversemyelitis pages 2-4).
Core Pathophysiology - Primary mechanisms: immune-mediated inflammation of the spinal cord, with adaptive humoral immunity central in NMOSD (AQP4-IgG binding to astrocytic AQP4, complement activation, perivascular deposition; necrotic LETM). In MOGAD, demyelinating pathology linked to anti-MOG antibodies; many cases are para-infectious. Idiopathic TM involves focal inflammatory demyelination with glial activation and axonal injury (NEJM; 2010; https://doi.org/10.1056/NEJMcp1001112). Distinct clinical sequelae such as spinal movement disorders are more prevalent in AQP4-IgG–positive NMOSD, aligning with greater tract involvement in extensive lesions (J Neurol; Jul 2024; https://doi.org/10.1007/s00415-024-12527-6) (frohman2010transversemyelitis pages 1-2, abboud2024spinalmovementdisorders pages 1-2, abboud2024spinalmovementdisorders pages 5-7). - Molecular pathways: antibody binding to AQP4 on astrocytic endfeet leading to classical complement cascade activation and astrocyte injury; secondary demyelination and axonal loss. Para-/post-infectious mechanisms include molecular mimicry and cross-reactivity between pathogen- or vaccine-derived antigens and myelin proteins (e.g., MBP, MOG). Proposed mechanisms in vaccine/infection-associated TM include mimicry and immune dysregulation (Ann Med & Surgery; Jul 2022; https://doi.org/10.1016/j.amsu.2022.103870) (frohman2010transversemyelitis pages 1-2, naeem2022theassociationbetween pages 3-4, naeem2022theassociationbetween pages 2-3). - Cellular processes: astrocyte injury (NMOSD) with downstream BBB disruption; oligodendrocyte/myelin injury (demyelination) prominent in idiopathic TM and MOGAD; microglial activation and myelin phagocytosis; axonal injury correlating with long-term disability (NEJM 2010; https://doi.org/10.1056/NEJMcp1001112; Arquivos de Neuro-Psiquiatria; Aug 2024; https://doi.org/10.1055/s-0044-1789342) (frohman2010transversemyelitis pages 1-2, silva2024longitudinallyextensivetransversemyelitis pages 10-11).
Key Molecular Players - Genes/Proteins (HGNC): - AQP4 (HGNC:633): target of AQP4-IgG in NMOSD; mediates complement-dependent cytotoxicity on astrocytes (NEJM 2010; https://doi.org/10.1056/NEJMcp1001112) (frohman2010transversemyelitis pages 1-2). - MOG (HGNC:7106): anti-MOG antibodies associated with inflammatory demyelination (MOGAD), including post-/para-infectious myelitis; Zika-associated cases with anti-MOG reported (Rev Inst Med Trop São Paulo; Dec 2024; https://doi.org/10.1590/S1678-9946202466066) (colognese2024zikavirusinfection pages 8-10, colognese2024zikavirusinfection pages 5-6). - Antibodies: AQP4-IgG; MOG-IgG; anti-ganglioside antibodies (GM1, GD1a, GD1b) observed in Zika-associated ATM indicating para-infectious autoimmunity (Dec 2024; https://doi.org/10.1590/S1678-9946202466066) (colognese2024zikavirusinfection pages 8-10, colognese2024zikavirusinfection pages 5-6). - Cell Types (CL): - Astrocytes (CL:0000127): primary cellular target in NMOSD astrocytopathy (NEJM 2010) (frohman2010transversemyelitis pages 1-2). - Oligodendrocytes (CL:0000128): demyelination in TM/MOGAD (NEJM 2010) (frohman2010transversemyelitis pages 1-2). - Microglia (CL:0000129): activation and cytokine/chemokine amplification; phagocytosis of myelin (NEJM 2010) (frohman2010transversemyelitis pages 1-2). - Neurons (CL:0000540): axonal injury contributes to persistent deficits (NEJM 2010; Arquivos de Neuro-Psiquiatria 2024) (frohman2010transversemyelitis pages 1-2, silva2024longitudinallyextensivetransversemyelitis pages 10-11). - Anatomical Locations (UBERON): spinal cord (UBERON:0002240); longitudinally extensive transverse myelitis (LETM) defined as lesions spanning ≥3 vertebral levels (NEJM 2010; https://doi.org/10.1056/NEJMcp1001112) (frohman2010transversemyelitis pages 2-4). - Chemical Entities (CHEBI) and Interventions: - High-dose corticosteroids (e.g., methylprednisolone) are first-line acute therapy; used across idiopathic/postinfectious and Zika-associated ATM (NEJM 2010; Zika review 2024) (frohman2010transversemyelitis pages 1-2, colognese2024zikavirusinfection pages 8-10). - Therapeutic plasma exchange (PLEX) is used for severe or steroid-refractory antibody-mediated myelitis; ongoing pragmatic Phase 3 trial testing early vs rescue PLEX (TIMELY-PLEX; NCT07100990; recruiting 2025) (NCT07100990).
Biological Processes (GO terms; suggested mappings) - Complement activation, classical pathway (GO:0006958/GO:0006956): implicated by perivascular Ig/complement deposition in NMOSD lesions (NEJM 2010) (frohman2010transversemyelitis pages 1-2). - Antibody-dependent cytotoxicity (GO:0001788) and humoral immune response (GO:0006959): central to AQP4-IgG–mediated injury (NEJM 2010) (frohman2010transversemyelitis pages 1-2). - Myelination/demyelination (GO:0042552/GO:0008366) and axon degeneration (GO:0030422): core pathological processes (NEJM 2010) (frohman2010transversemyelitis pages 1-2). - Astrocyte activation (GO:0048143), microglial activation (GO:0001774), inflammatory response (GO:0006954): observed in TM lesions (NEJM 2010) (frohman2010transversemyelitis pages 1-2). - Blood–brain barrier disruption (GO:0035633 as related processes): secondary to astrocyte injury in NMOSD (NEJM 2010) (frohman2010transversemyelitis pages 1-2).
Cellular Components (GO terms; suggested mappings) - Astrocyte endfoot and perivascular space (perivascular endfeet enriched for AQP4) where Ig/complement deposition occurs in NMOSD lesions (NEJM 2010) (frohman2010transversemyelitis pages 1-2). - Myelin sheath (GO:0043209) and node of Ranvier: loci of demyelination and conduction failure (NEJM 2010) (frohman2010transversemyelitis pages 1-2). - Extracellular space/perivascular regions for immune complex deposition; cytotoxic effectors likely operate at astrocyte plasma membrane AQP4 assemblies (NEJM 2010) (frohman2010transversemyelitis pages 1-2).
Disease Progression - Sequence of events: 1) Trigger (infection, vaccination, systemic autoimmune disease; parasitic or viral infections in some cases) leads to immune activation (NEJM 2010; Zika systematic review 2024) (frohman2010transversemyelitis pages 1-2, colognese2024zikavirusinfection pages 5-6). 2) Autoantibody generation or dysregulated cell-mediated responses drive spinal cord inflammation; in NMOSD, AQP4-IgG binds astrocytes, activates complement; in MOGAD, anti-MOG promotes demyelinating attack (NEJM 2010; Zika review 2024) (frohman2010transversemyelitis pages 1-2, colognese2024zikavirusinfection pages 8-10). 3) Lesion formation: perivascular immune deposition, astrocyte loss and demyelination, axonal injury; MRI shows intramedullary T2 hyperintense lesions with enhancement acutely (NEJM 2010) (frohman2010transversemyelitis pages 2-4). 4) Clinical nadir within hours to 3 weeks; recovery phase mostly within 3 months; residual disability correlates with lesion extent and nadir severity (NEJM 2010; Arquivos 2024 LETM cohort) (frohman2010transversemyelitis pages 1-2, silva2024longitudinallyextensivetransversemyelitis pages 10-11). - Staging/phases: prodromal infectious symptoms (if present) → acute inflammatory phase with rapid neurological worsening → subacute stabilization → recovery/remodeling with potential chronic sequelae (NEJM 2010; Zika systematic review 2024) (frohman2010transversemyelitis pages 1-2, colognese2024zikavirusinfection pages 5-6).
Phenotypic Manifestations and Outcomes - Core phenotypes: bilateral motor deficits (paresis/paraplegia), sensory level, Lhermitte’s sign, sphincter/autonomic dysfunction (urinary retention/incontinence, constipation) (NEJM 2010) (frohman2010transversemyelitis pages 2-4, naeem2022theassociationbetween pages 1-2). - Spinal movement disorders: highly prevalent across non-MS inflammatory myelopathies—73% overall; most frequent in AQP4-IgG–positive NMOSD (92%) and least frequent in MOGAD (57%). Phenomena include tonic spasms (57%), focal dystonia (25%), spinal tremor (16%), spontaneous clonus (9.5%), secondary restless limb syndrome (9.5%), and spinal myoclonus (8%). LETM and AQP4-IgG were independent risk factors for movement disorders; MOG-IgG was associated with lower risk. Resolution at mean 11 months occurred in 19.5%, partial improvement in 37%, and persistent/worsening in 43% (J Neurol; Jul 2024; https://doi.org/10.1007/s00415-024-12527-6) (abboud2024spinalmovementdisorders pages 1-2, abboud2024spinalmovementdisorders pages 5-7). - LETM long-term outcomes: In a 10-year follow-up cohort of first-episode LETM (n=39), final diagnoses included 51% monophasic seronegative LETM, 28% AQP4-IgG NMOSD, 7.7% seronegative NMOSD, 5% MOGAD, 5% recurrent seronegative LETM, and 2.6% MS. Mortality reached 10% (median time to death 3 years). Severe disability (EDSS ≥7) persisted in 17% of survivors; higher age at onset and higher EDSS at nadir predicted worse outcomes (Arquivos de Neuro-Psiquiatria; Aug 2024; https://doi.org/10.1055/s-0044-1789342) (silva2024longitudinallyextensivetransversemyelitis pages 10-11).
Triggers and Special Etiologies - Post-/para-infectious triggers: Zika virus infection has been associated with ATM, sometimes with coinfection by dengue or chikungunya. Proposed mechanisms include direct neurotropism, systemic immune activation, and para-infectious autoimmunity (antiganglioside and anti-MOG antibodies). Mixed infection presentations showed shorter prodrome and worse disability than isolated ATM. MRI often shows multilevel cervical/thoracic T2 hyperintense lesions; enhancement is variable; brain involvement can co-occur. In a synthesis of 20 subjects, 6/14 isolated ATM had mRS ≤3, while 5/6 mixed cases had mRS 4–5 at short follow-up (Rev Inst Med Trop São Paulo; Dec 2024; https://doi.org/10.1590/S1678-9946202466066) (colognese2024zikavirusinfection pages 6-8, colognese2024zikavirusinfection pages 5-6, colognese2024zikavirusinfection pages 8-10). - Parasitic infection: case-based literature documents schistosomiasis-associated myelitis; details in 2024 reports emphasize the importance of differential diagnosis in endemic settings, though mechanistic specifics are limited in the available excerpt (Arquivos de Neuro-Psiquiatria; Oct 2024; https://doi.org/10.1055/s-0045-1806986) (frohman2010transversemyelitis pages 1-2). - Vaccination: TM has been reported after vaccines including COVID-19; hypothesized mechanisms include molecular mimicry and immune cross-reactivity (e.g., spike protein with myelin proteins). CSF in reported cases often shows elevated protein and pleocytosis; MRI shows intramedullary hyperintense lesions. Causality remains uncertain and mechanisms are incompletely understood (Ann Med & Surgery; Jul 2022; https://doi.org/10.1016/j.amsu.2022.103870) (naeem2022theassociationbetween pages 3-4, naeem2022theassociationbetween pages 2-3).
CSF/MRI Biomarkers - MRI: acute gadolinium-enhancing intramedullary lesions; LETM defined by ≥3 vertebral segments carries greater morbidity; in Zika-associated ATM, lesions may be extensive from cervical levels to conus, sometimes non-enhancing and with concurrent brain lesions (NEJM 2010; Zika 2024) (frohman2010transversemyelitis pages 2-4, colognese2024zikavirusinfection pages 6-8, colognese2024zikavirusinfection pages 5-6). - CSF: pleocytosis, elevated IgG index, or oligoclonal bands may support inflammatory myelitis; Zika-associated cases showed variable pleocytosis with sometimes low protein; pathogen PCR/IgM may be positive (NEJM 2010; Zika 2024) (frohman2010transversemyelitis pages 2-4, colognese2024zikavirusinfection pages 5-6).
Current applications and real-world implementations - Acute treatment: high-dose IV corticosteroids remain first-line; PLEX is used as escalation or for antibody-mediated disease (NEJM 2010) (frohman2010transversemyelitis pages 1-2). - Clinical trials: TIMELY-PLEX (NCT07100990), a pragmatic randomized Phase 3 trial, is evaluating early concurrent PLEX versus rescue PLEX after high-dose corticosteroids for severe optic neuritis and transverse myelitis; outcomes include EDSS at 6 months for TM and visual measures for ON (ClinicalTrials.gov; recruiting 2025) (NCT07100990).
Expert opinions and analysis - The NEJM review emphasizes immune-mediated pathogenesis, particularly antibody/complement mechanisms in NMOSD, and recommends full spinal MRI with contrast and CSF analysis to confirm inflammation and exclude mimics. Prognosis relates to lesion extent, severity at nadir, and underlying etiology (NEJM 2010) (frohman2010transversemyelitis pages 1-2, frohman2010transversemyelitis pages 2-4). - Prospective observational data underscore clinical distinctions among NMOSD, MOGAD, and idiopathic TM, with AQP4-IgG and LETM conferring higher risk for movement complications and indicating more extensive tract involvement—consistent with antibody-mediated astrocytopathy leading to secondary demyelination (J Neurol 2024) (abboud2024spinalmovementdisorders pages 1-2, abboud2024spinalmovementdisorders pages 5-7).
Relevant statistics and data - Incidence: idiopathic/postinfectious TM estimated 1.3–8/million annually; 15–30% remain idiopathic (NEJM 2010; Aug 2010) (frohman2010transversemyelitis pages 1-2). - Outcomes: LETM 10-year cohort—10% mortality, 17% severe disability among survivors; higher age at onset and higher EDSS nadir predicted worse outcomes (Arquivos; Aug 2024) (silva2024longitudinallyextensivetransversemyelitis pages 10-11). - Movement disorders: 73% overall prevalence across myelitis types; 92% in AQP4-IgG NMOSD vs 57% in MOGAD; tonic spasms 57% (J Neurol; Jul 2024) (abboud2024spinalmovementdisorders pages 1-2, abboud2024spinalmovementdisorders pages 5-7). - Zika-associated ATM: in short-term follow-up, 6/14 isolated ATM achieved mRS ≤3; mixed presentations frequently had mRS 4–5; dysautonomia present in a minority (Rev Inst Med Trop São Paulo; Dec 2024) (colognese2024zikavirusinfection pages 5-6, colognese2024zikavirusinfection pages 6-8).
Gene/protein annotations with ontology terms (HGNC, GO) and structured entities - AQP4 (HGNC:633): biological processes—complement activation (GO:0006956), humoral immune response (GO:0006959). Cellular component—astrocyte plasma membrane/perivascular endfeet. Evidence: NEJM 2010 (frohman2010transversemyelitis pages 1-2). - MOG (HGNC:7106): biological processes—myelination/demyelination (GO:0042552/GO:0008366). Evidence: Zika-associated anti-MOG; J Neurol distinctions (colognese2024zikavirusinfection pages 8-10, abboud2024spinalmovementdisorders pages 1-2). - Complement components (process-level): classical pathway activation in NMOSD lesions (NEJM 2010) (frohman2010transversemyelitis pages 1-2).
Phenotype associations (HP terms; examples) - Pyramidal weakness/paraparesis, sensory level, Lhermitte’s sign, urinary retention/incontinence, constipation; spinal movement disorders (tonic spasms, dystonia, tremor, clonus). Evidence: NEJM 2010; J Neurol 2024 (frohman2010transversemyelitis pages 2-4, abboud2024spinalmovementdisorders pages 1-2, abboud2024spinalmovementdisorders pages 5-7).
Cell type involvement (CL terms) - Astrocytes (CL:0000127), oligodendrocytes (CL:0000128), microglia (CL:0000129), neurons (CL:0000540) (NEJM 2010; Arquivos 2024) (frohman2010transversemyelitis pages 1-2, silva2024longitudinallyextensivetransversemyelitis pages 10-11).
Anatomical locations (UBERON terms) - Spinal cord (UBERON:0002240); LETM spans ≥3 vertebral segments (NEJM 2010) (frohman2010transversemyelitis pages 2-4).
Chemical entities (CHEBI terms; interventions) - Glucocorticoids (e.g., methylprednisolone) and therapeutic plasma exchange used acutely (NEJM 2010; ClinicalTrials.gov 2025) (frohman2010transversemyelitis pages 1-2, NCT07100990).
Evidence items with URLs/date - Frohman EM, Wingerchuk DM. Transverse Myelitis. NEJM. Aug 2010. https://doi.org/10.1056/NEJMcp1001112 (frohman2010transversemyelitis pages 1-2, frohman2010transversemyelitis pages 2-4) - Abboud H et al. Spinal movement disorders in NMOSD, MOGAD, and idiopathic TM. J Neurol. Jul 2024. https://doi.org/10.1007/s00415-024-12527-6 (abboud2024spinalmovementdisorders pages 1-2, abboud2024spinalmovementdisorders pages 5-7) - Silva PBR et al. Longitudinally-extensive transverse myelitis: 10-year cohort. Arquivos de Neuro-Psiquiatria. Aug 2024. https://doi.org/10.1055/s-0044-1789342 (silva2024longitudinallyextensivetransversemyelitis pages 10-11) - Colognese BA, Argollo N. Zika infection and acute transverse myelitis: systematic review. Rev Inst Med Trop São Paulo. Dec 2024. https://doi.org/10.1590/S1678-9946202466066 (colognese2024zikavirusinfection pages 8-10, colognese2024zikavirusinfection pages 6-8, colognese2024zikavirusinfection pages 5-6) - Naeem FN et al. SARS‑CoV‑2 vaccines and transverse myelitis: review. Ann Med & Surgery. Jul 2022. https://doi.org/10.1016/j.amsu.2022.103870 (naeem2022theassociationbetween pages 3-4, naeem2022theassociationbetween pages 1-2, naeem2022theassociationbetween pages 2-3) - TIMELY-PLEX Trial. ClinicalTrials.gov Identifier: NCT07100990. Recruiting (planned 2025 start). https://clinicaltrials.gov/ct2/show/NCT07100990 (NCT07100990)
Key artifact | Entity type | Name | Ontology ID | Role in pathophysiology (1–2 sentences) | Evidence / citation (DOI or URL) | Evidence ID | |---|---|---|---|---|---| | Gene/Protein | Aquaporin-4 (AQP4) | HGNC:633 | AQP4 is the target antigen in NMOSD; AQP4-IgG binding leads to complement-mediated astrocyte injury with perivascular Ig/complement deposition and can produce necrotic, longitudinally extensive lesions. | https://doi.org/10.1056/NEJMcp1001112 (NEJM review) | (frohman2010transversemyelitis pages 1-2, abboud2024spinalmovementdisorders pages 1-2) | | Gene/Protein | Myelin oligodendrocyte glycoprotein (MOG) | HGNC:7106 | Anti-MOG antibodies are associated with an inflammatory demyelinating myelitis phenotype (MOGAD), often para-infectious, characterized by prominent demyelination with distinct clinical/imaging features from AQP4-NMOSD. | https://doi.org/10.1590/S1678-9946202466066 (Zika–ATM review noting anti‑MOG) | (colognese2024zikavirusinfection pages 8-10, abboud2024spinalmovementdisorders pages 1-2) | | Cell type | Astrocyte | CL:0000127 | Astrocytes (AQP4-expressing endfeet) are primary targets in NMOSD; astrocyte loss triggers secondary inflammation, blood–brain barrier disruption, and downstream demyelination. | https://doi.org/10.1056/NEJMcp1001112 | (frohman2010transversemyelitis pages 1-2) | | Cell type | Oligodendrocyte | CL:0000128 | Oligodendrocyte dysfunction or loss underlies demyelination in TM and MOGAD; inflammatory mediators and antibody/opsonization can lead to myelin loss and impaired conduction. | https://doi.org/10.1056/NEJMcp1001112 | (frohman2010transversemyelitis pages 1-2) | | Cell type | Microglia | CL:0000129 | Microglial activation contributes to lesion inflammation, phagocytosis of myelin, and secretion of cytokines/chemokines that amplify tissue injury. | https://doi.org/10.1056/NEJMcp1001112 | (frohman2010transversemyelitis pages 1-2) | | Cell type | Neuron | CL:0000540 | Axonal and neuronal injury within the cord cause persistent disability; axonal loss correlates with poor long-term outcomes after severe TM/LETM. | https://doi.org/10.1056/NEJMcp1001112; https://doi.org/10.1055/s-0044-1789342 | (frohman2010transversemyelitis pages 1-2, silva2024longitudinallyextensivetransversemyelitis pages 10-11) | | Tissue | Spinal cord | UBERON:0002240 | The spinal cord is the anatomical locus of TM; longitudinally extensive transverse myelitis (LETM, ≥3 vertebral segments) associates with greater morbidity and mortality. | https://doi.org/10.1056/NEJMcp1001112; https://doi.org/10.1055/s-0044-1789342 | (frohman2010transversemyelitis pages 1-2, silva2024longitudinallyextensivetransversemyelitis pages 10-11) | | Intervention | High-dose corticosteroids | none | First-line acute immunotherapy to suppress spinal cord inflammation in ATM; commonly used in idiopathic, postinfectious, and Zika-associated cases. | https://doi.org/10.1056/NEJMcp1001112; https://doi.org/10.1590/S1678-9946202466066 | (frohman2010transversemyelitis pages 1-2, colognese2024zikavirusinfection pages 8-10) | | Intervention | Therapeutic plasma exchange (PLEX) | none | PLEX is used for severe or steroid-refractory antibody-mediated myelitis; a randomized trial (TIMELY-PLEX) is testing early versus rescue PLEX timing in inflammatory myelitis. | https://clinicaltrials.gov/ct2/show/NCT07100990 | (NCT07100990) | | Antibody | Anti-ganglioside antibodies (GM1, GD1a, GD1b) | none | Anti-ganglioside antibodies have been reported in Zika-associated ATM and may reflect para-infectious autoimmunity contributing to motor dysfunction via complement/Fc-mediated mechanisms. | https://doi.org/10.1590/S1678-9946202466066 | (colognese2024zikavirusinfection pages 8-10) |
Table: Table summarizing principal genes/proteins, cell types, tissues, interventions, and antibodies implicated in transverse myelitis and related disorders, with ontology IDs and cited evidence (pqac IDs) for quick reference in a disease knowledgebase.
Notes on scope and limitations - Cytokine/chemokine-specific profiles and detailed lesion immunohistochemistry beyond complement/Ig deposition were not available in the extracted sources and remain areas for further sourcing. Where possible, we relied on a high-quality NEJM review for core mechanisms and 2024 studies for recent developments and outcomes (frohman2010transversemyelitis pages 1-2, abboud2024spinalmovementdisorders pages 1-2, silva2024longitudinallyextensivetransversemyelitis pages 10-11, colognese2024zikavirusinfection pages 8-10).
References
(frohman2010transversemyelitis pages 1-2): Elliot M. Frohman and Dean M. Wingerchuk. Transverse myelitis. New England Journal of Medicine, 363:564-572, Aug 2010. URL: https://doi.org/10.1056/nejmcp1001112, doi:10.1056/nejmcp1001112. This article has 265 citations and is from a highest quality peer-reviewed journal.
(frohman2010transversemyelitis pages 2-4): Elliot M. Frohman and Dean M. Wingerchuk. Transverse myelitis. New England Journal of Medicine, 363:564-572, Aug 2010. URL: https://doi.org/10.1056/nejmcp1001112, doi:10.1056/nejmcp1001112. This article has 265 citations and is from a highest quality peer-reviewed journal.
(abboud2024spinalmovementdisorders pages 1-2): Hesham Abboud, Rongyi Sun, Nikhil Modak, Mohamed Elkasaby, Alexander Wang, and Michael Levy. Spinal movement disorders in nmosd, mogad, and idiopathic transverse myelitis: a prospective observational study. Journal of Neurology, 271:5875-5885, Jul 2024. URL: https://doi.org/10.1007/s00415-024-12527-6, doi:10.1007/s00415-024-12527-6. This article has 6 citations and is from a domain leading peer-reviewed journal.
(abboud2024spinalmovementdisorders pages 5-7): Hesham Abboud, Rongyi Sun, Nikhil Modak, Mohamed Elkasaby, Alexander Wang, and Michael Levy. Spinal movement disorders in nmosd, mogad, and idiopathic transverse myelitis: a prospective observational study. Journal of Neurology, 271:5875-5885, Jul 2024. URL: https://doi.org/10.1007/s00415-024-12527-6, doi:10.1007/s00415-024-12527-6. This article has 6 citations and is from a domain leading peer-reviewed journal.
(naeem2022theassociationbetween pages 3-4): Fatima Naz Naeem, Syeda Fatima Saba Hasan, Muskaan Doulat Ram, Summaiyya Waseem, Syed Hassan Ahmed, and Taha Gul Shaikh. The association between sars-cov-2 vaccines and transverse myelitis: a review. Annals of Medicine & Surgery, Jul 2022. URL: https://doi.org/10.1016/j.amsu.2022.103870, doi:10.1016/j.amsu.2022.103870. This article has 14 citations and is from a poor quality or predatory journal.
(naeem2022theassociationbetween pages 2-3): Fatima Naz Naeem, Syeda Fatima Saba Hasan, Muskaan Doulat Ram, Summaiyya Waseem, Syed Hassan Ahmed, and Taha Gul Shaikh. The association between sars-cov-2 vaccines and transverse myelitis: a review. Annals of Medicine & Surgery, Jul 2022. URL: https://doi.org/10.1016/j.amsu.2022.103870, doi:10.1016/j.amsu.2022.103870. This article has 14 citations and is from a poor quality or predatory journal.
(silva2024longitudinallyextensivetransversemyelitis pages 10-11): Paula Baleeiro Rodrigues Silva, Samira Luisa Apóstolos-Pereira, Graziella Aguiar Santos Faria, Sara Terrim, Flávio Vieira Marques Filho, Mariana Gondim Peixoto Spricigo, Mateus Boaventura de Oliveira, Guilherme Diogo Silva, Douglas Kazutoshi Sato, and Tarso Adoni. Longitudinally-extensive transverse myelitis: impact on functional prognosis and mortality in a 10-year follow-up cohort. Arquivos de Neuro-Psiquiatria, Aug 2024. URL: https://doi.org/10.1055/s-0044-1789342, doi:10.1055/s-0044-1789342. This article has 0 citations and is from a peer-reviewed journal.
(colognese2024zikavirusinfection pages 8-10): Bianca Aparecida Colognese and Nayara Argollo. Zika virus infection and acute transverse myelitis: a comprehensive systematic review. Revista do Instituto de Medicina Tropical de São Paulo, Dec 2024. URL: https://doi.org/10.1590/s1678-9946202466066, doi:10.1590/s1678-9946202466066. This article has 2 citations.
(colognese2024zikavirusinfection pages 5-6): Bianca Aparecida Colognese and Nayara Argollo. Zika virus infection and acute transverse myelitis: a comprehensive systematic review. Revista do Instituto de Medicina Tropical de São Paulo, Dec 2024. URL: https://doi.org/10.1590/s1678-9946202466066, doi:10.1590/s1678-9946202466066. This article has 2 citations.
(NCT07100990): John J Chen. Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX). Mayo Clinic. 2025. ClinicalTrials.gov Identifier: NCT07100990
(naeem2022theassociationbetween pages 1-2): Fatima Naz Naeem, Syeda Fatima Saba Hasan, Muskaan Doulat Ram, Summaiyya Waseem, Syed Hassan Ahmed, and Taha Gul Shaikh. The association between sars-cov-2 vaccines and transverse myelitis: a review. Annals of Medicine & Surgery, Jul 2022. URL: https://doi.org/10.1016/j.amsu.2022.103870, doi:10.1016/j.amsu.2022.103870. This article has 14 citations and is from a poor quality or predatory journal.
(colognese2024zikavirusinfection pages 6-8): Bianca Aparecida Colognese and Nayara Argollo. Zika virus infection and acute transverse myelitis: a comprehensive systematic review. Revista do Instituto de Medicina Tropical de São Paulo, Dec 2024. URL: https://doi.org/10.1590/s1678-9946202466066, doi:10.1590/s1678-9946202466066. This article has 2 citations.
Transverse myelitis (TM) represents a focal inflammatory disorder of the spinal cord characterized by immune-mediated demyelination and axonal injury that results in acute neurological dysfunction affecting sensorimotor and autonomic systems[1][33][37]. The condition demonstrates significant pathobiological heterogeneity, with multiple etiological pathways converging on a final common pathway of spinal cord inflammation, myelin destruction, and neuronal injury. This report synthesizes current understanding of the molecular and cellular mechanisms underlying TM pathophysiology, emphasizing the dysregulated immune processes, pathogenic molecular mediators, and the sequence of events leading from initial trigger to clinical manifestation and potential recovery.
The fundamental pathophysiological process in transverse myelitis involves dysregulated immune responses targeting components of the central nervous system, particularly the myelin sheath and associated glial cells within the spinal cord[1][2]. Rather than representing a pure demyelinating disorder, TM emerges as a mixed inflammatory condition involving multiple cellular and tissue compartments. The histopathophysiology varies considerably depending on the underlying etiology, but classical presentations are characterized by perivascular infiltration, demyelination, and axonal injury mediated by monocytes and lymphocytes at lesion sites[1][2][13]. The heterogeneous nature of TM pathology, manifested by involvement of both gray and white matter with variable degrees of inflammation across different cases, demonstrates that multiple immunological mechanisms can produce the characteristic clinical syndrome of acute spinal cord dysfunction[1][2].
The initial trigger for this inflammatory cascade differs markedly across TM etiologies but frequently involves either direct pathogenic infection or molecular mimicry following viral or bacterial infection[3][22]. In idiopathic cases, which represent the majority of TM presentations, the immune system mounts an abnormal and excessive response against the spinal cord in the absence of any identifiable external trigger[2][4]. The body's inflammatory response, which normally functions to eliminate infectious agents or repair injured tissue, becomes pathologically dysregulated and targets the healthy myelin insulation covering nerve fibers in the spinal cord[2][4]. This aberrant immune activation represents a fundamental departure from normal immune homeostasis, wherein protective inflammatory mechanisms become destructive to host tissue.
Multiple interconnected molecular pathways drive the inflammatory cascade in transverse myelitis, with distinct patterns emerging depending on the underlying etiology. The dysregulated pathways encompass classical and alternative complement activation, T cell and B cell mediated autoimmunity, cytokine-driven inflammation, and blood-brain barrier disruption. Understanding these pathways provides crucial insight into disease mechanisms and identifies potential therapeutic targets.
Recent investigations have identified interleukin-6 (IL-6) as a particularly critical mediator in TM pathogenesis. Research examining cerebrospinal fluid (CSF) from TM patients revealed that IL-6 levels are selectively and dramatically elevated, with approximately 300-fold mean induction relative to control patients[17]. Remarkably, IL-6 levels in CSF were 262-fold higher in acute TM cases compared to controls, whereas serum IL-6 did not differ significantly, suggesting that IL-6 is generated within the central nervous system rather than entering from peripheral circulation[17]. Immunohistochemical analysis of spinal cord autopsy specimens from deceased TM patients demonstrated that astrocytes constitute the predominant source of IL-6 production within inflammatory lesions, with microglial cells and infiltrating immune cells contributing less robustly to IL-6 secretion[17].
The cytopathic effects of IL-6 operate through STAT3 phosphorylation at Tyr705 in microglial cells, which is critical for mediating IL-6-induced neural injury[17]. Critically, IL-6 demonstrates both necessity and sufficiency for inducing the characteristic spinal cord injury observed in TM patients, as demonstrated through organotypic spinal cord cultures and animal models of TM[17]. IL-6 directly correlates with markers of tissue injury and sustained clinical disability in TM patients, establishing this cytokine as a key pathogenic effector linking inflammation to neurological dysfunction[17]. The mechanism involves IL-6 stimulation of astrocyte IL-6 production through a positive feedback loop, amplifying the inflammatory signal within the lesion microenvironment[17].
Interleukin-17 (IL-17) production from peripheral blood mononuclear cells is markedly elevated in TM patients compared to healthy controls, multiple sclerosis patients, and other neurological diseases[14]. TM patients demonstrate approximately 8.4-fold higher IL-17 levels compared to MS patients and substantially higher levels compared to controls and other neurological diseases, with mean IL-17 levels of 302.6 pg/ml in TM versus 36.1 pg/ml in controls[14]. This elevated IL-17 production parallels and likely amplifies IL-6 levels, as IL-17 regulates the production of proinflammatory cytokines including TNF-α, IL-1β, and IL-6, all of which stimulate IL-6 production by astrocytes[14]. The relationship between IL-17 and IL-6 suggests that Th17 cell differentiation and IL-17 production represent critical events in TM immunopathogenesis, with IL-17 functioning as an amplifier of the inflammatory cascade already initiated by IL-6.
The complement system, particularly in antibody-mediated TM presentations such as neuromyelitis optica spectrum disorder (NMOSD), drives pathogenic astrocyte destruction and neuroinflammation[31][34]. When pathogenic aquaporin-4 (AQP4) immunoglobulin G antibodies bind to AQP4 on astrocyte membranes, they initiate complement activation through the classical pathway[31]. This cascade culminates in the enzymatic cleavage of complement component C5 into two highly active fragments: C5a, a potent anaphylatoxin, and C5b, which initiates assembly of the terminal complement complex C5b-9, also termed the membrane attack complex (MAC)[31][34]. The MAC functions as a pore-forming structure that inserts into the astrocyte membrane, causing osmotic dysregulation and rapid astrocyte death through complement-dependent cytotoxicity[31][34].
C5a operates as a powerful chemotactic factor recruiting and activating inflammatory cells, particularly neutrophils, driving a robust inflammatory infiltrate into CNS lesions[34]. C5aR and C3aR signaling involve the pertussis-toxin-sensitive G-protein G_αi with downstream activation of intracellular calcium, PI3K, Akt, and MAPK pathways, resulting in production of reactive oxygen species, pro-inflammatory mediators including IL-6 and TNF-α, histamine, and adhesion molecules[31]. Beyond direct complement-mediated astrocytolysis, bystander injury mechanisms contribute to tissue damage, wherein local diffusion of soluble C5b67 complexes produced by complement activation on astrocytes results in MAC formation on nearby bystander cells[31]. Antibody-dependent cellular cytotoxicity (ADCC) mechanisms also participate, with leukocytes activated by IgG binding to AQP4 on astrocytes causing targeted injury to adjacent cells through exocytosis of toxic granule contents[31].
The biological effects of complement activation extend beyond cytotoxicity to encompass leukocyte chemotaxis and recruitment of inflammatory cells. Bystander injury and complement-mediated leukocyte recruitment suggest that complement-targeted therapeutics may offer particular value in antibody-mediated TM presentations. C5 inhibition through monoclonal antibodies such as eculizumab and ravulizumab acts as a "circuit breaker," immediately blocking the final common pathway of tissue destruction by preventing C5 cleavage and thereby abolishing both C5a generation and MAC formation[31][34].
Alternative histopathologic mechanisms in TM include molecular mimicry and superantigen-mediated disease, both operating through immune cross-reactivity mechanisms[1][19]. Molecular mimicry occurs when an infectious agent displays molecular structures that resemble epitopes within the spinal cord or myelin[22]. When the body mounts an immune response to the invading pathogen, it simultaneously responds to spinal cord molecules sharing structural characteristics with pathogen epitopes, leading to misdirected immune attack on host CNS tissue[22]. This mechanism has particular relevance in post-infectious TM presentations, wherein TM develops following recovery from a primary infection, suggesting that pathogen clearance has occurred while misdirected autoimmune responses persist.
Superantigen-mediated mechanisms bypass conventional MHC-peptide-TCR interactions by directly cross-linking MHC class II molecules on antigen-presenting cells with T cell receptors, causing massive polyclonal T cell activation independent of specific antigen recognition[1][3]. This leads to robust pro-inflammatory cytokine production and autoreactive T cell expansion. These alternative mechanisms likely operate alongside classical antigen-specific immune responses in various TM etiologies and contribute to the heterogeneous pathobiological features observed across the TM disease spectrum.
The blood-brain barrier (BBB) dysfunction represents a critical early pathological event enabling immune cell infiltration into the spinal cord parenchyma. The BBB comprises endothelial cells interconnected by tight junctions, with pericytes and astrocyte endfeet forming the neurovascular unit (NVU). Breakdown of BBB integrity occurs through both paracellular and transcellular pathways[15]. Paracellular permeability increases via breakdown of tight junctions when inflammatory cytokines including TNF-α and IFN-γ activate BBB endothelial cells by upregulating proinflammatory signals such as NF-κB, resulting in decreased tight junction protein expression[15].
Transcellular leukocyte migration across the BBB occurs via coordinated activation of cell adhesion molecules on endothelial cells and their corresponding ligands on lymphocytes. Lymphocytes express very late antigen-4 (VLA-4) and lymphocyte function-associated antigen-1 (LFA-1), which couple with endothelial cell receptors VCAM-1 and ICAM-1, respectively, to mediate leukocyte arrest and transmigration[15]. VCAM-1 upregulation in BBB endothelial cells around active or inactive lesions suggests that endothelial activation precedes demyelination formation[15]. Additional adhesion molecules including melanoma cell adhesion molecule (MCAM), activated leukocyte cell adhesion molecule (ALCAM), and diapedesis-promoting integrin and costimulatory molecule (DICAM) orchestrate trafficking of specific immune cell subsets, particularly pathogenic Th1 and Th17 cells[15].
Endothelial cells can be directly targeted by pathogenic autoantibodies, as demonstrated in NMOSD where autoantibodies against glucose-regulated protein 78 (GRP78) on brain microvascular endothelial cells activate these cells and induce claudin-5 downregulation and enhanced macromolecule transit[18]. These mechanisms collectively represent a fundamental shift in BBB function from a protective barrier to a gateway facilitating CNS immune infiltration.
Astrocytes and microglial cells play pivotal roles in TM pathophysiology beyond their role as IL-6 producers. Astrocyte activation and microglial activation represent hallmark features of TM histopathology[12][25]. In NMOSD-associated TM, astrocytes activated by AQP4-IgG binding undergo loss of AQP4 expression yet remain initially viable, establishing a "precytolytic" phase wherein astrocytes are activated but not yet lysed[26]. During this precytolytic phase, astrocytes signal to microglia via complement fragment C3a, derived from upregulated astrocytic complement C3 protein[26].
Microglial C3a receptor (C3aR) signaling emerges as critical for progression beyond the precytolytic phase, with C3aR-deficient mice showing attenuated microglial activation and motor impairment despite ongoing astrocyte activation and AQP4 downregulation[26]. Confocal imaging reveals striking physical coalescence of astrocytes and microglia following NMO-IgG-mediated astrocyte activation, with microglial processes converging toward activated astrocytes[26]. This astrocyte-microglia crosstalk thus represents a previously underappreciated mechanism driving disease progression and motor deficits in NMO-associated TM, suggesting that microglia serve as critical effectors of neuronal dysfunction following astrocyte activation.
The microglial contribution to TM extends beyond astrocyte-microglia interactions to include direct effects on neurons and axons. Microglial-derived pro-inflammatory mediators, reactive oxygen species, and proteases can directly damage neuronal structures. Additionally, microglial phagocytic activity may contribute to myelin and axonal debris clearance but can also result in excess neural tissue destruction if uncontrolled.
Aquaporin-4 (AQP4), a water channel protein localized to astrocyte plasma membranes particularly at perivascular endfeet, represents the primary autoantigen in approximately 40% of neuromyelitis optica spectrum disorder (NMOSD) cases and a substantial subset of severe TM presentations[1][7][10]. The AQP4 protein mediates water transport across astrocyte membranes, essential for osmoregulation and astrocyte volume control[7]. Circulating anti-AQP4 immunoglobulin G autoantibodies directly initiate astrocyte injury upon binding to extracellular epitopes of AQP4, triggering complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity mechanisms[7][31]. The presence of anti-AQP4 antibodies in serum demonstrates robust specificity for NMOSD, with nearly perfect positive predictive value for the diagnosis when combined with appropriate clinical and imaging findings.
Longitudinally extensive transverse myelitis (LETM), defined as spinal cord lesions extending over three or more vertebral segments with more than two-thirds of cord thickness involvement, shows particularly high association with anti-AQP4 seropositivity. In one study examining recurrent TM patients, anti-AQP4 antibody positivity increased from 26.9% overall to 41.2% among LETM cases[7]. The presence of anti-AQP4 antibodies in LETM predicts higher disability scores and increased likelihood of disease recurrence and conversion to NMO[7][10]. While anti-AQP4 seropositivity predicts recurrent disease course, it does not necessarily predict long-term disability outcome, suggesting that multiple pathogenic mechanisms contribute to final clinical outcomes beyond AQP4-IgG activity.
Myelin oligodendrocyte glycoprotein (MOG) represents an alternative primary autoantigen in a subset of TM cases, particularly in MOG antibody-associated disease (MOGAD)[8][11]. MOG comprises an extracellular domain on the outer surface of oligodendrocyte myelin sheaths and is exposed on cell surfaces of both oligodendrocytes and myelin-producing cells. Anti-MOG antibodies in MOGAD patients target these exposed epitopes, leading to demyelination and CNS inflammation[8]. MOGAD presents as the second most common presentation of MOG antibody disease overall, occurring in approximately 26% of affected patients[8].
Importantly, TM in MOGAD typically presents with better neurological outcomes compared to AQP4-IgG-positive NMOSD, with MOGAD TM patients demonstrating lower average expanded disability status scale (EDSS) scores than AQP4-Ab positive NMOSD patients[8]. However, MOGAD-associated TM frequently involves the conus medullaris, predisposing to persistent bladder dysfunction with up to 59% experiencing long-term bladder symptoms compared to 48% in AQP4-positive NMOSD[8]. A major diagnostic challenge in MOGAD-associated TM involves fluctuating MOG antibody seropositivity, with antibody levels varying over time, occasionally disappearing and reappearing, and the possibility of initially normal MRI in up to 10% of patients[8].
Both CD4+ and CD8+ T cells contribute substantially to TM pathophysiology through multiple mechanisms. Th17 cells, differentiated through the combined action of TGF-β plus IL-6, with IL-21 and IL-23 enhancing their precursor frequency and stabilizing their phenotype, represent particularly pathogenic T cell subsets in TM[38]. Th17 cells express the transcription factor RORC and produce IL-17, IL-21, and IL-22, all of which promote endothelial activation, increase trans-endothelial migration of neutrophils and eosinophils, and amplify local inflammation[15][38]. Compared to MS patients, TM patients display higher proportions of Th17 cells and IL-17-producing CD8+ T cells in peripheral blood, suggesting that TM represents a Th17-driven autoimmune disease[38].
The relationship between T cells and B cells in TM involves critical cross-talk in both directions[38]. B cells, beyond their role as antibody producers, serve as antigen-presenting cells and produce IL-6, potentially skewing T cells toward a Th17 response[38]. Conversely, Th17 cells provide very effective help to B cells, facilitating germinal center formation and autoantibody production[38]. In AQP4-IgG seropositive NMOSD, NMO-IgG is produced peripherally rather than intrathecally, with antibody-producing plasmablasts and plasma cells not recruited to the subarachnoid space[38]. This peripheral generation of pathogenic antibodies indicates that T cell help occurs in secondary lymphoid organs rather than within the CNS, representing a fundamental distinction from MS wherein intrathecal antibody production occurs.
Genetic predisposition significantly influences TM susceptibility and clinical manifestations. Specific human leukocyte antigen (HLA) alleles confer risk for NMOSD-associated TM, with HLA-DRB108:02 and HLA-DRB116:02 identified as risk alleles while HLA-DRB1*09:01 confers protection[20][23]. The potassium channel gene KCNMA1, which encodes large-conductance calcium-activated potassium channel alpha 1 subunit, associates with disability and transverse myelitis in NMOSD, with immunohistochemical detection in perivascular endfeet of astrocytes and markedly diminished immunoreactivity in active spinal cord lesions[20][23]. This suggests that KCNMA1-mediated potassium channel dysfunction in astrocytes may impair osmoregulation and contribute to cellular injury.
MS genetic risk alleles outside the major histocompatibility complex region also contribute to NMOSD susceptibility, though with lesser effect sizes than in MS[20]. The MS genetic burden score in NMOSD patients is significantly higher than in healthy controls, suggesting that genetic factors conferring MS risk partially overlap with those for TM and NMOSD[20].
The characteristic histopathological distribution of TM lesions, with perivascular infiltration of inflammatory cells, reflects the predilection for vascular-associated immune infiltration[1][3][6]. Monocyte and lymphocyte infiltration concentrates around small blood vessels within the spinal cord, establishing inflammatory foci that subsequently spread to involve adjacent parenchyma. The involvement of both gray and white matter in TM lesions represents a departure from classical demyelinating patterns and indicates that neurons and neuronal cell bodies are targeted alongside myelin-producing oligodendrocytes.
Gray matter involvement in TM produces distinctive lower motor neuron (LMN) features, urinary retention, and a more devastating but often monophasic clinical course, distinct from white matter myelitis with upper motor neuron (UMN) features and more indolent but potentially recurrent courses[35][40]. This distinction suggests fundamentally different pathological processes target motor neurons directly versus corticospinal tract axons. Anterior horn cell dysfunction, as detected through electromyography, predicts poor long-term recovery prognosis, indicating that neuronal loss carries particular prognostic significance[40].
Oligodendrocytes and myelin sheaths represent primary targets of TM pathogenic mechanisms. Demyelination in TM arises from both direct oligodendrocyte injury through antibody-mediated and T cell-mediated mechanisms and from bystander demyelination secondary to inflammatory mediator release. The heterogeneous histopathology, with variable degrees of demyelination, axonal injury, and astroglial and microglial activation, indicates multiple potentially overlapping mechanisms of oligodendrocyte and myelin injury operating across different TM etiologies.
Oligodendrocyte progenitor cells (OPCs) represent potential therapeutic targets for remyelination, with research demonstrating that human glial restricted progenitor cells can integrate into spinal cord-demyelinated lesions and remyelinate lesions while supporting damaged axons[6][21]. The capacity for endogenous remyelination exists within the injured spinal cord but is frequently insufficient to fully restore myelin or neurological function, suggesting that therapeutic enhancement of remyelination capacity may improve long-term outcomes.
The temporal progression of transverse myelitis follows a relatively stereotyped pattern despite variable etiologies, with symptom onset ranging from acute onset within hours to subacute progression over four weeks[2][25][41]. The characteristic progression to nadir occurs between 4 hours and 21 days after symptom onset, representing a critical diagnostic feature[1][2][13][25]. This rapid progression reflects the acute inflammatory nature of the disorder and contrasts sharply with the much slower progression in many other myelopathies.
The sequence of pathophysiological events likely proceeds as follows: initial trigger (infection, molecular mimicry, or unknown factors in idiopathic cases) activates innate and adaptive immune responses; BBB disruption allows immune cell infiltration into the spinal cord; activated T cells and B cells, along with innate immune cells, infiltrate the cord parenchyma; astrocytes become activated by direct contact with immune cells and exposure to pro-inflammatory cytokines; complement and antibody-mediated mechanisms target antigens on astrocytes and oligodendrocytes; IL-6 and IL-17 production drives amplification of inflammation; microglia become activated and interact with astrocytes in AQP4-IgG-mediated disease; myelin destruction proceeds through demyelination; axonal injury and neuronal dysfunction occur; and clinical manifestations emerge reflecting the spinal cord level and degree of tissue injury.
The rapid clinical progression to nadir likely reflects the acute inflammatory and demyelinating processes overwhelming the spinal cord's limited capacity for compensatory adaptation. Demyelination blocks action potential propagation along axons, leading to immediate functional deficit. Axonal injury and cell death may accumulate rapidly during the acute inflammatory phase.
Idiopathic transverse myelitis, comprising the majority of TM cases, occurs in the absence of identifiable external triggers yet demonstrates clear evidence of immune-mediated tissue injury[1][2][4]. The underlying pathophysiological mechanism in idiopathic TM is postulated to involve an immune response to a virus that the body has cleared and is no longer detectable, with the immune system remaining activated and mistakenly attacking the spinal cord wiring[2]. This scenario implies that initial viral infection triggers immune activation through pattern recognition and provides antigenic epitopes; the virus is subsequently cleared from the body; yet the activated immune response persists and becomes redirected against self-antigens through molecular mimicry or epitope spreading mechanisms; and immune attack on the myelin sheath ensues.
Post-infectious TM develops following recovery from viral or bacterial infection, suggesting that immune responses initiated against pathogens become misdirected to the spinal cord[1][22][37]. Numerous infectious agents associate with TM, including enteroviruses, West Nile virus, herpes viruses, HIV, HTLV-1, Zika virus, neuroborreliosis from Lyme disease, Mycoplasma, and Treponema pallidum[1][4][37]. The temporal relationship between infection and TM onset, with TM developing days to weeks after infectious symptom resolution, supports post-infectious rather than direct viral infection of the spinal cord as the primary mechanism in many cases[22].
Molecular mimicry represents the leading proposed mechanism in post-infectious TM, wherein pathogenic epitopes share structural features with CNS antigens[22]. When immune responses target the pathogenic epitope, cross-reactivity with self-antigens ensues. Viral superantigens represent an alternative mechanism, causing polyclonal T cell expansion independent of specific antigen recognition and generating a pool of autoreactive T cells that secondarily attack CNS tissue[3].
Multiple systemic inflammatory autoimmune disorders associate with TM, including systemic lupus erythematosus (SLE), Sjögren syndrome (SS), Behçet disease, sarcoidosis, antiphospholipid syndrome, and others[1][35][40][43]. In these contexts, TM arises from dysregulated systemic autoimmunity with secondary CNS involvement. SLE-associated TM typically presents with longitudinally extensive lesions and more severe clinical courses requiring aggressive immunosuppression[43]. The presence of oligoclonal bands in CSF and elevated IgG index in SLE-related TM indicates intrathecal immunoglobulin synthesis, suggesting active CNS autoimmunity within the spinal cord microenvironment[40].
Sjögren syndrome-associated TM frequently affects the cervical cord and may manifest as LETM[43]. Spinal cord involvement occurs in 20-35% of SS patients and may represent the initial disease manifestation in approximately 20%[35]. SS-associated TM often proves refractory to corticosteroid monotherapy, requiring more aggressive immunosuppressive approaches including intravenous cyclophosphamide[43].
Antiphospholipid antibody syndrome-associated TM likely involves interactions between circulating antiphospholipid antibodies and spinal cord phospholipids, with resulting thrombotic or inflammatory complications[43]. CSF findings typically reveal neutrophilic pleocytosis with elevated protein and occasionally elevated IgG index[35].
Paraneoplastic TM occurs as a remote neurological complication of malignancy, particularly in association with specific paraneoplastic antibodies such as anti-CRMP-5 (collapsin response mediator protein-5) in small cell lung carcinoma[35][40]. These antibodies target CNS antigens cross-reactive with tumor antigens, and remission of the underlying malignancy may lead to TM improvement.
Rare cases of TM have been anecdotally reported following vaccination, including vaccinations against rabies, diphtheria-tetanus-polio, pertussis, MMR, influenza, hepatitis B, and recently COVID-19[4][42]. One theory suggests that vaccination may jumpstart an autoimmune process in genetically susceptible individuals, though the exact mechanisms remain unclear[4]. Importantly, extensive research has demonstrated that vaccines are safe, and any association with TM may be coincidental or represent an exceptionally rare complication[4]. The temporal association between vaccination and TM onset, occurring within days to three months, suggests that if a causal relationship exists, it likely involves vaccine-triggered immune activation rather than vaccine components causing direct CNS injury[4].
Motor weakness, typically progressing rapidly and reaching peak deficit within days to weeks, reflects damage to corticospinal tracts and gray matter motor neurons[2][33][37][41]. At peak deficit, 50% of patients present with complete paraplegia, illustrating the severity of motor pathway disruption[2][19]. Upper motor neuron signs predominate when white matter lesions damage corticospinal tracts, while lower motor neuron signs emerge when lesions directly involve anterior horn cells in gray matter[40][43]. The progression from initial flaccidity to subsequent spasticity reflects evolving stages of spinal shock and neuronal reorganization.
The lesion level determines which motor systems are affected, with thoracic lesions (affecting 70% of cases) causing lower extremity weakness and gait disturbance, cervical lesions (20% of cases) potentially affecting upper extremities and breathing through phrenic nerve involvement, and lumbosacral lesions (10% of cases) causing lower extremity weakness[1][2][13]. The rapid development and severity of motor deficits reflect the acute inflammatory demyelination and axonal injury mechanisms rather than gradual progressive myelin loss or neurodegeneration typical of chronic disorders.
The sensory level, defined as a clearly demarcated boundary below which sensation is reduced or absent, represents a hallmark physical finding in TM and emerges from spinal cord transection or near-transection of sensory pathways[1][2][4][35]. Approximately 80% of TM patients present with a clearly defined sensory level[25]. Sensory symptoms generally affect the lesion level or 1-2 levels above or below the lesion, reflecting the anatomical distribution of the inflammatory lesion. Abnormal sensations including dysesthesia (unpleasant, burning sensation), paresthesia (tingling, "pins and needles" sensation), and allodynia (pain from light touch normally non-painful) occur in 80-94% of TM patients[4][25][47].
The pathophysiological basis for sensory dysfunction involves demyelination of spinothalamic and dorsal column fibers, disrupting the normal transmission of pain, temperature, and proprioceptive information to the brain. The distinctive band-like sensation wrapping around the torso reflects the transverse nature of the spinal cord lesion affecting both sides, creating a level boundary at the lesion rostral margin[4][47].
Autonomic dysfunction represents an almost universal finding in acute TM, with virtually all patients experiencing some degree of bladder or bowel dysfunction at peak deficit[2][19]. The acute phase features urinary retention due to spinal shock affecting parasympathetic sacral autonomic fibers, followed by development of hyperreflexic, spastic bladder or flaccid atonic bladder depending on the stage of spinal shock resolution[22]. Bowel dysfunction typically manifests as constipation acutely and may progress to incontinence. Sexual dysfunction occurs frequently, with men experiencing erectile dysfunction and both genders experiencing difficulty achieving orgasm[36][48].
The pathophysiology involves damage to autonomic nerve fibers within the spinal cord, particularly at the conus medullaris where sacral parasympathetic fibers concentrate[40][43]. Conus-localized lesions produce particularly prominent early and severe sphincter and sexual dysfunction[40][43]. The presence of prominent bladder dysfunction at presentation may paradoxically indicate central cord involvement where autonomic fibers are concentrated, thus potentially predicting worse neurological outcomes[22].
Back pain, occurring in 80-95% of TM patients, typically precedes or accompanies motor and sensory symptoms[6][25]. The pain frequently localizes to the thoracic or lumbar region corresponding to the lesion location. The pathophysiological basis for pain in TM likely involves several mechanisms: inflammatory irritation of spinal nerve roots or meningeal structures, ischemia from impaired spinal cord blood flow, and dysfunction of pain-processing systems following demyelination. Sharp, radiating pain shooting down extremities or wrapping around the trunk suggests root involvement or sensory pathway irritation.
Immediately after acute TM onset, spinal shock develops over approximately three weeks, a period of transient depression of neural activity below the lesion producing flaccid paralysis, absent reflexes, and suppressed autonomic function[22]. Following spinal shock resolution, gradual recovery of reflex function occurs, often accompanied by transition to spastic paralysis with hyperreflexia. The distinction between these phases has prognostic significance, with patients demonstrating persistent lower motor neuron features beyond the expected spinal shock duration showing poor long-term recovery prognosis[43].
Long-term disability outcomes vary dramatically across the TM spectrum: approximately 33% recover with little to no lasting deficits, 33% develop moderate permanent disability, and 33% experience severe permanent disability[2][13][19][24]. Pain and spasticity represent the most frequent long-term complications, affecting quality of life substantially even in patients with otherwise good motor recovery[36]. Persistent sexual dysfunction, depression, anxiety, and social isolation constitute additional long-term consequences of TM with significant impact on patient wellbeing[36][48].
Recognition that TM represents a syndrome rather than a disease entity with single etiology necessitates careful differential diagnosis to exclude other myelopathies that mimic TM clinically and radiographically. Conditions that must be excluded include compressive myelopathy from herniated discs, vertebral body compression fractures, epidural abscesses or masses, and spondylitis[1][37]. Vascular causes including spinal cord infarction from anterior spinal artery occlusion must be excluded, as these require distinct management strategies. Metabolic and nutritional causes such as vitamin B12 deficiency or copper deficiency present with similar clinical features but have entirely different pathophysiology and treatment approaches[35][40]. Neoplasms, both primary intramedullary and metastatic, may present acutely with myelitic features. Radiation myelitis from prior spinal cord radiation represents another important mimic. Guillain-Barré syndrome, an ascending motor paralysis from peripheral nerve involvement, must be distinguished from TM through clinical examination and electrodiagnostic testing[1].
Recovery from acute TM proceeds through multiple mechanisms encompassing natural resolution of inflammation, remyelination, axonal regeneration, and plastic reorganization of spinal cord circuits. Most recovery occurs within the first three months after symptom onset, though improvements continue for up to two years[1][2][13][21]. Intensive physical and occupational therapy initiated early maximizes functional recovery by promoting activity-dependent neural repair mechanisms[21][53].
Myelin repair through oligodendrocyte progenitor cell (OPC) proliferation and differentiation into new myelinating oligodendrocytes represents an important endogenous repair mechanism, though it frequently occurs incompletely. Emerging therapeutic approaches including stem cell transplantation and remyelination-promoting therapies aim to enhance these natural repair processes[27][30]. Mesenchymal stem cells and neural progenitor cells secrete neurotrophic growth factors, modulate inflammation, and promote axonal regeneration and remyelination when delivered to lesion sites[27][30].
Neuroplasticity mechanisms, whereby preserved neural circuits reorganize and develop new functional connections to bypass damage, contribute substantially to functional recovery even without histological myelin repair[21][53]. Spinal cord reorganization can redirect motor commands through alternative pathways, permitting recovery of function despite persistent demyelination.
Transverse myelitis emerges as a pathophysiologically diverse yet clinically recognizable syndrome of acute spinal cord inflammation and demyelination. Multiple molecular and cellular mechanisms converge from distinct etiological pathways to produce the characteristic clinical manifestations of rapidly progressive motor, sensory, and autonomic dysfunction. Dysregulated immune responses targeting components of the myelin-glia-neuronal complex result from both identifiable external triggers and intrinsic immune dysregulation in idiopathic cases. The heterogeneous histopathology reflecting variable involvement of gray and white matter, different cell types, and multiple pathogenic mechanisms indicates that TM encompasses multiple disease entities with overlapping clinical presentations. Understanding these underlying pathophysiological mechanisms provides a foundation for developing targeted therapeutic interventions aimed at suppressing pathogenic immune responses while promoting endogenous repair processes.